MDT-AP-2494
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- new_clusters
- C2
- umap1_2d
- 1.797300467
- umap2_2d
- 0.46005018
- umap1_3d
- -0.533066319
- umap2_3d
- -1.20002186
- umap3_3d
- 0.061885929
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.670
- MYC_TARGETS_V1+0.660
- E2F_TARGETS+0.470
- MTORC1_SIGNALING+0.450
- OXIDATIVE_PHOSPHORYLATION+0.440
- G2M_CHECKPOINT+0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.320
- UNFOLDED_PROTEIN_RESPONSE+0.280
- ALLOGRAFT_REJECTION+0.270
- INFLAMMATORY_RESPONSE+0.260
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.370
- MITOTIC_SPINDLE-0.340
- HEME_METABOLISM-0.320
- NOTCH_SIGNALING-0.310
- HEDGEHOG_SIGNALING-0.260
- PROTEIN_SECRETION-0.260
- INTERFERON_ALPHA_RESPONSE-0.200
- TGF_BETA_SIGNALING-0.200
- UV_RESPONSE_DN-0.190
- PI3K_AKT_MTOR_SIGNALING-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0203 | Med | Medulloblastoma | 0.853 |
| 2 | BS_R439VVPK | Med | Medulloblastoma | 0.839 |
| 3 | MNG952 | — | — | 0.821 |
| 4 | MNG158 | — | — | 0.814 |
| 5 | MDT-AP-2281 | Med | Medulloblastoma | 0.800 |
| 6 | TCGA-66-2795-01A-02R-0980-07 | — | cohortSQ2 | 0.797 |
| 7 | MDT-AP-0549 | Med | Medulloblastoma | 0.790 |
| 8 | TCGA-PQ-A6FN-01A-11R-A31N-07 | — | — | 0.789 |
| 9 | MDT-AP-0509 | Med | Medulloblastoma | 0.787 |
| 10 | SRR975564 | — | — | 0.787 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.670 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.660 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.450 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |